Evelo Biosciences, Inc.
evelobio.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2023 10-Q, filed Nov 9, 2023. Its latest SEC filing is a EFFECT from Mar 8, 2024.
10-Q for Q3 FY2023, filed Nov 9, 2023
The sections below describe the company as of the FY2022 annual report.
What Did They Do?
Develops oral medicines made from selected microbes and the particles they release to treat people with inflammatory diseases.
10-K for FY2022, filed Mar 16, 2023Evelo is a clinical-stage biotechnology company focused on discovering and developing a new class of oral medicines that act on immune…View ↗
This discovery may create the potential for a new type of effective, safe, well tolerated, and convenient medicine for people with many…View ↗
We are developing SINTAX medicines - whole, inactivated microbes and microbial EVs - to engage cells in the small intestine and drive…View ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2023, filed Nov 10, 2023
−$12.4MView ↗
- ▼ −60% (Loss)
- vs −$30.6M in Q3 FY2022
-
Dec 4, 2023
Nasdaq moved to delist Evelo’s shares
Evelo said it would not appeal; trading was set to be suspended on December 12, 2023.
Sources
8-K, filed Dec 4, 2023
Accordingly, Nasdaq notified the Company that continued listing of its securities on Nasdaq is no longer warranted and, unless the Company…View ↗
-
Nov 21, 2023
Board approved a plan to dissolve Evelo
The plan is subject to stockholder approval; the CEO and CFO departed as Evelo prepared to wind down.
Sources
8-K, filed Nov 21, 2023
On November 20, 2023, in connection with the Dissolution, Simba Gill ceased serving as the Company’s President, Chief Executive Officer…View ↗
Adds microbial vesicles
The earlier report describes oral medicines made from single microbial strains; the latest report also develops extracellular vesicles released by microbes as a product type.
10-K for FY2019, filed Feb 14, 2020 10-K for FY2022, filed Mar 16, 2023Our first product candidates are monoclonal microbials: orally delivered pharmaceutical compositions derived from naturally occurring…View ↗
Who Did They Compete With?
Competes with AbbVie, Johnson & Johnson, Pfizer, Novartis International, Regeneron Pharmaceuticals, Sanofi, Bristol Myers Squibb, Amgen, Arcutis Biotherapeutics, Roivant Sciences, and Incyte
10-K for FY2022, filed Mar 16, 2023In autoimmune or inflammatory diseases, we may be challenged by a wide range of competitors. In later, more severe stages of disease, the…View ↗
Loading...
